HHC-O and HHC-P - semi-synthetic derivatives of HHC (guide)
HHC-O i HHC-P — co to, jak dziala i na co. Zrozumialy przewodnik u Bucha.
HHC appeared on the European market around 2022 as a 'legal substitute for THC'. Before regulators could react, producers went a step further and introduced new generations of derivatives: HHC-O with an acetate group and HHC-P with an elongated carbon chain. Both compounds are more active than the base HHC and operate in a legal gray area that is rapidly narrowing. The article explains exactly what these derivatives are, how they differ from HHC and from each other, what science says, and what their current legal status is in Poland and the EU.
KEY INFORMATION
• HHC-O and HHC-P are semi-synthetic derivatives of HHC - they are obtained from HHC in the laboratory and are not naturally present in the cannabis plant in significant amounts.
• HHC-P has a heptyl chain (7 carbon atoms), which theoretically increases affinity for the CB1 receptor by up to 30 times compared to pentyl analogs - according to the Pfaffer-Merkle rule applied to THC.
• In Poland, HHC and its derivatives are not (as of mid-2026) explicitly mentioned in the Act on Counteracting Drug Addiction, but the legal situation is dynamic (EMCDDA, Drug Profile HHC, 2024).
• France, Germany, and Austria have already banned HHC - the rest of the EU will likely follow suit.
What is HHC and where do its derivatives come from?
HHC (hexahydrocannabinol) is a hydrogenated form of THC - chemically similar, but with a modified cyclohexane ring instead of cyclohexene. Hydrogenation (adding hydrogen atoms) makes the molecule more chemically stable and resistant to oxidation. HHC occurs naturally in trace amounts in cannabis pollen and seeds, but commercial products contain HHC produced synthetically from CBD or terpenes, e.g., from limonene through multi-step chemical reactions.
Why did producers turn to HHC derivatives? The answer is simple: HHC made it onto the controlled substances lists in several EU countries, so chemists sought analogs that are structurally similar but not yet named in legal documents. This is how HHC-O and HHC-P emerged - both molecules modify HHC in a way that increases its activity while simultaneously (at least for a time) allowing them to avoid legal scrutiny.
This is not a new phenomenon - the same race for 'analogs' occurred with synthetic cannabinoids (Spice/K2), which Europe experienced from 2010 to 2020 with very negative health consequences for users. The EMCDDA regularly warns in its reports about the use of substances from this group without appropriate safety data.
HHC-O - prodrug with an acetate group
HHC-O (hexahydrocannabinol acetate, also written as HHC-acetate) is HHC with an added acetate group (-OCOCH₃) at position C-9. The mechanism of action is analogous to delta-8-THC-O: the acetyl modification acts as a prodrug - the molecule itself is inactive, but after absorption, enzymes in the body cleave the acetate group and release active HHC.
The consequence of this mechanism is increased lipophilicity (fat solubility), which translates to better bioavailability when inhaled and a longer duration of action. Users describe the effects of HHC-O as more intense and longer-lasting than HHC alone. However, there are no clinical studies comparing both compounds under controlled conditions - all available data is based on user reports and in vitro pharmacological analyses.
There is also the issue of thermal safety. Other compounds with acetate groups - including diacetylmorphine (heroin) and EVALI-related vitamin E acetate - have shown that acetate groups in inhalation products can be toxic to the respiratory tract. There are no direct studies linking HHC-O to lung damage, but the analogy is sufficiently concerning to treat this compound with particular caution.
HHC-P - heptyl analog with high receptor activity
HHC-P (hexahydrocannabinol-heptyl) differs from HHC by one modification: instead of a five-carbon side chain (pentyl), it has a seven-carbon heptyl chain. This difference of one carbon atom has significant pharmacological implications.
The Pfaffer-Merkle rule, derived from studies on THC and its analogs, states that extending the side chain of cannabinoids from five to seven carbon atoms dramatically increases affinity for the CB1 receptor. In the case of the THC-P analog (THCP), discovered by Italian scientists in 2019, the affinity for CB1 was 33 times higher than that of THC (Citti et al., Scientific Reports, 2019). It is assumed that a similar relationship applies to HHC-P in relation to HHC.
Higher affinity for the CB1 receptor does not automatically mean 'better' or more pleasant effects. It primarily means a higher risk of adverse effects in case of overdose - paranoia, anxiety, rapid heartbeat, disorientation - which can be significantly more pronounced with stronger compounds than with THC alone. Users of HHC-P report online effects similar to very strong THC at low doses, which supports the hypothesis of high CB1 activity, but available data is purely anecdotal.
HHC, HHC-O and HHC-P - comparison table
The three compounds from the HHC family differ in structure, mechanism of action, and potential strength. The table below gathers the most important differences in one place.
| Parameter | HHC | HHC-O | HHC-P |
|---|---|---|---|
| Full name | Hexahydrocannabinol | HHC acetate | HHC heptyl |
| Side chain | Pentyl (C5) | Pentyl + acetate | Heptyl (C7) |
| Mechanism of action | Direct CB1 agonist | Prodrug → active HHC | Strong CB1 agonist (C7) |
| Relative potency (CB1) | Base (1×) | Higher bioavailability | Szacunkowo 10-33× silniejszy |
| Origin | Trace natural; commercially synthetic | Fully synthetic | Fully synthetic |
| Clinical trials | Minimal | None | None |
| Legal status in Poland (2026) | Gray area | Gray area | Gray area |
Legal status of HHC-O and HHC-P in Poland and the EU
The Polish Act on Counteracting Drug Addiction (consolidated text Dz.U. 2023 item 1939) contains lists of controlled substances - I-P, II-P, III-P for psychotropic substances and I-N, II-N, III-N, IV-N for narcotics. HHC, HHC-O, and HHC-P do not appear in these lists by name as of mid-2026. However, the regulations contain "analogue" and "similar substances" clauses - their application to HHC derivatives is subject to legal interpretation, which may vary depending on the court.
In several EU countries, HHC is already formally banned. France added HHC to the list of narcotic substances in July 2023. Germany placed HHC under control within the BtMG (Betäubungsmittelgesetz) in 2023, during a general reform of drug law. Austria and Sweden included HHC on the lists of new psychoactive substances (NPS). The EMCDDA in its substance profile from 2024 identifies HHC and its derivatives as a priority for monitoring by member states (EMCDDA, Drug Profile HHC, 2024).
Practical conclusion: selling and possessing HHC-O or HHC-P in Poland may be legal today and illegal in three months. The legal dynamics in this space is very rapid. Before purchasing or possessing any products containing these compounds, it is advisable to consult a lawyer or follow the current announcements from the Chief Sanitary Inspectorate and GIS.
Frequently Asked Questions
What is HHC-O and how does it differ from HHC?
HHC-O (hexahydrocannabinol acetate) is a derivative of HHC enriched with an acetate group. Similar to delta-8-THC-O in relation to delta-8-THC, the acetate is a prodrug: in the body, an enzyme cleaves the acetate group, releasing active HHC. This results in higher bioavailability than HHC alone, and the effects may be stronger and longer-lasting. HHC-O is a fully synthetic compound - it is not found naturally in the cannabis plant in this form.
What is HHC-P and why is it considered stronger?
HHC-P (hexahydrocannabinol-heptyl) is an analog of HHC with an extended side chain containing seven carbon atoms instead of five. According to the Pfaffer-Merkle rule confirmed for THCP (Citti et al., Scientific Reports, 2019), the extension of the chain to C7 can increase affinity for the CB1 receptor by up to 33 times. This is why HHC-P is described as one of the strongest derivatives of HHC, although there is a lack of clinical studies on humans.
Are HHC-O and HHC-P legal in Poland in 2026?
The legal status of HHC-O and HHC-P in Poland is ambiguous. The Act on Counteracting Drug Addiction does not mention these compounds by name, but the "analogue" clauses may apply. In France, Germany, and Austria, HHC is already banned. The EMCDDA recommends monitoring and controlling these compounds throughout the EU (EMCDDA, 2024). The situation is dynamic - the law can change quickly.
What are the differences between HHC, HHC-O, and HHC-P?
HHC is a hydrogenated form of THC with a saturated ring structure - more stable than THC, but less binding to the CB1 receptor. HHC-O has an added acetate group that increases bioavailability. HHC-P has an extended heptyl chain, which radically increases affinity for CB1. HHC is the basic compound, HHC-O is HHC with better absorption, and HHC-P is HHC with significantly higher receptor activity and correspondingly higher risk of adverse effects.
Where in the EU are HHC and its derivatives already banned?
By 2026, HHC and its derivatives have been subjected to drug control in several EU countries: Germany banned HHC in 2023 as part of the amendment to the BtMG, Austria and Sweden have HHC on the lists of new psychoactive substances (NPS), and France listed HHC as a controlled substance in 2023. Poland and several other EU countries do not yet have regulations directly banning HHC and its derivatives, although the EMCDDA recommends monitoring these compounds..
This article is for informational and educational purposes and does not constitute legal advice. The legal status described in the article is valid as of the publication date - regulations regarding cannabis may change. Consult a lawyer or current legal acts before making decisions.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
